Edition:
United Kingdom

Proteon Therapeutics Inc (PRTO.OQ)

PRTO.OQ on NASDAQ Stock Exchange Global Market

1.85USD
18 Oct 2018
Change (% chg)

$0.06 (+3.35%)
Prev Close
$1.79
Open
$1.76
Day's High
$1.88
Day's Low
$1.76
Volume
2,028
Avg. Vol
8,731
52-wk High
$2.90
52-wk Low
$1.50

Latest Key Developments (Source: Significant Developments)

Proteon Therapeutics Posts Q2 Loss Per Share $0.28
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Proteon Therapeutics Inc ::PROTEON THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.28.Q2 EARNINGS PER SHARE VIEW $-0.36 -- THOMSON REUTERS I/B/E/S.  Full Article

Proteon Therapeutics Q3 ‍loss per share $1.08​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Proteon Therapeutics Inc :Proteon Therapeutics announces third quarter 2017 financial results.Remain on-track to complete enrollment in Q1 of 2018 in patency-2, co's second phase 3 clinical trial of vonapanitase​.Qtrly ‍loss per share $1.08​.Expects its cash, cash equivalents, available-for-sale investments will be sufficient to fund its operations into Q4 of 2019,.Q3 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.  Full Article

Proteon Therapeutics announces data from trial of investigational vonapanitase in patients with CKD
Tuesday, 13 Dec 2016 

Proteon Therapeutics Inc : Secondary and tertiary endpoint data and enrollment in second phase 3 ongoing . Trial did not meet primary efficacy endpoint .Announces top-line data from phase 3 patency-1 clinical trial of investigational vonapanitase in patients with CKD.  Full Article